Moderna is a Cambridge, Massachusetts-based biotechnology company that has built its operating model around messenger RNA (mRNA), a technology it has used to develop vaccines and therapeutics for infectious disease, oncology, and rare disease. The company is best known for Spikevax, its COVID-19 vaccine, but it now markets three approved products and is advancing a pipeline aimed at up to 10 additional product approvals through 2027.
Moderna reported approximately $1.9 billion in revenue for 2025, down sharply from prior years as COVID-19 vaccination rates normalized, while research and development spending totaled roughly $3.1 billion. The company employs around 4,700 people, a workforce it has explicitly chosen not to scale to match its product ambitions. Instead, Moderna executives have stated that they intend to bring up to 15 new products to market over five years — a goal they argue would require a headcount in the hundreds of thousands under a traditional operating model.
That gap between ambition and headcount is the throughline connecting Moderna’s AI strategy. The company has invested in artificial intelligence both to multiply the output of its existing employees and to compress the scientific timelines that have historically made drug development slow and expensive.
